Alnylam was tight-lipped this week after CEO John Maraganore suggested that an increasingly competitive market might force the firm to abandon its AMD candidate.
But officials at Alnylam rival Acuity Pharmaceuticals remained upbeat about their VEGF-targeting drug, Cand5, after recent data showed that that the competing VEGF compound Lucentis, co-developed by Genentech and Novartis, may be an effective treatment for the condition.
Get the full story with
GenomeWeb Premium
Only $95 for the
first 90 days*
GenomeWeb Premium gives you:
✔ Full site access
✔ Interest-based email alerts
✔ Access to archives
Never miss another important industry story.
Try GenomeWeb Premium now.
Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.
*Before your trial expires, we’ll put together a custom quote with your long-term premium options.
